Skip to main content
Year archive

PERCHERON THERAPEUTICS LIMITED — 2021 filings

All 61 regulatory filings released by PERCHERON THERAPEUTICS LIMITED (PER) in 2021, sourced directly from the official regulator.

61 Filings
2021 Period
2021 filings (61)
Filing Released Lang
Application for quotation of securities - ANP 6 pages 27.7KB
Share Issue/Capital Change
2021-12-23 English
Cleansing Notice 1 page 178.8KB
Capital/Financing Update
2021-12-23 English
Proposed issue of securities - ANP 5 pages 27.3KB
Capital/Financing Update
2021-12-22 English
Entitlement Offer Results 2 pages 85.5KB
Capital/Financing Update
2021-12-21 English
Application for quotation of securities - ANP 6 pages 27.8KB
Capital/Financing Update
2021-12-21 English
Notification regarding unquoted securities - ANP 5 pages 26.7KB
Share Issue/Capital Change
2021-12-21 English
Change of Director's Interest Notice (MD) 2 pages 267.1KB
Director's Dealing
2021-12-21 English
Appendix 3G 5 pages 222.5KB
Share Issue/Capital Change
2021-12-16 English
Final Director's Interest Notice (GM, RM) 4 pages 254.0KB
Director's Dealing
2021-12-15 English
Final Director's Interest Notice (WG) 2 pages 225.2KB
Director's Dealing
2021-12-15 English
Annual General Meeting Presentation 21 pages 2.3MB
AGM Information
2021-12-14 English
Results of Annual General Meeting 2 pages 215.7KB
Declaration of Voting Results & Voting Rights Announcements
2021-12-14 English
Positive UK PIP Decision & PDCO opinion ratification by EMA 2 pages 127.4KB
Regulatory Filings
2021-12-13 English
ATL1102 Toxicology Protocol submitted to US FDA 2 pages 102.1KB
Regulatory Filings
2021-12-08 English
Update - Proposed issue of securities - ANP 12 pages 47.5KB
Capital/Financing Update
2021-11-22 English
Entitlement Offer Closing Date Extended 2 pages 169.0KB
Capital/Financing Update
2021-11-22 English
Notice of Annual General Meeting/Proxy Form 27 pages 647.9KB
AGM Information
2021-11-14 English
Change of Director's Interest Notice - CG 3 pages 280.5KB
Director's Dealing
2021-11-10 English
Becoming a substantial holder 3 pages 141.1KB
Regulatory Filings
2021-11-07 English
Placement and Cleansing Notice 1 page 133.7KB
Capital/Financing Update
2021-11-04 English
Application for quotation of securities - ANP 6 pages 27.7KB
Capital/Financing Update
2021-11-04 English
Prospectus 50 pages 421.7KB
Capital/Financing Update
2021-11-04 English
Positive PDCO opinion and A$20m Placement 5 pages 264.1KB
Capital/Financing Update
2021-10-31 English
Proposed issue of securities - ANP 13 pages 49.2KB
Capital/Financing Update
2021-10-31 English
Investor Presentation 42 pages 2.5MB
Investor Presentation
2021-10-31 English
Quarterly Report and Appendix 4C 9 pages 365.8KB
Interim / Quarterly Report
2021-10-28 English
Appendix 4G and Corporate Governance Statement 22 pages 423.3KB
Governance Information
2021-10-28 English
2021 Annual Report 60 pages 3.7MB
Annual Report
2021-10-28 English
Trading Halt 2 pages 239.7KB
Regulatory Filings
2021-10-27 English
Initial Director's Interest Notice 2 pages 243.4KB
Director's Dealing
2021-10-07 English
Antisense Therapeutics appoints new Non-Executive Director 2 pages 104.2KB
Board/Management Information
2021-10-03 English
Positive feedback received on Paediatric Investigation Plan 2 pages 152.1KB
Regulatory Filings
2021-09-29 English
New data supports ATL1102s broader clinical potential 4 pages 298.2KB
Capital/Financing Update
2021-09-23 English
ANP to present new proteomics data at WMS Congress 2021 2 pages 106.4KB
Regulatory Filings
2021-09-19 English
Appendix 4E and Full Year Statutory Accounts 76 pages 2.5MB
Annual Report
2021-08-24 English
ANP to participate in development of DMD Guidance for FDA 2 pages 148.0KB
Regulatory Filings
2021-08-23 English
ANP Updates on US Regulatory Plans for ATL1102 in DMD 2 pages 102.6KB
Regulatory Filings
2021-08-11 English
Quarterly Report and Appendix 4C 9 pages 433.0KB
Interim / Quarterly Report
2021-07-28 English
Antisense Therapeutics transitions to new Board Chair 2 pages 163.4KB
Board/Management Information
2021-07-27 English
ANP and MCRI new R&D collaboration for ATL1102 3 pages 179.2KB
Regulatory Filings
2021-06-27 English
ATL1102 for DMD EMA PIP feedback and FDA regulatory progress 2 pages 150.8KB
Regulatory Filings
2021-06-21 English
US FDA Feedback on Type C Meeting for ATL1102 in the US 2 pages 150.4KB
Regulatory Filings
2021-05-31 English
Manufacture of ATL1102 clinical supplies for Phase IIb trial 2 pages 100.3KB
Capital/Financing Update
2021-05-25 English
Proposed issue of Securities - ANP 5 pages 27.4KB
Capital/Financing Update
2021-05-06 English
Appendix 2A & Cleansing Notice 15 pages 410.4KB
Capital/Financing Update
2021-05-06 English
Quarterly Report and Appendix 4C 8 pages 339.0KB
Interim / Quarterly Report
2021-04-27 English
US FDA Type C Meeting for ATL1102 in DMD 2 pages 85.3KB
Regulatory Filings
2021-04-22 English
Initial Director's Interest Notice - CG 2 pages 239.0KB
Director's Dealing
2021-03-23 English
Antisense Therapeutics appoints new Non-Executive Director 2 pages 170.7KB
Board/Management Information
2021-03-21 English
Appendix 3G 13 pages 346.8KB
Capital/Financing Update
2021-03-18 English
FDA Rare Disease Day 2021 1 page 79.6KB
Regulatory Filings
2021-03-03 English
Jett Foundation 4th Annual Rare Disease Day 2 pages 108.2KB
Regulatory Filings
2021-02-25 English
ATL1102 DMD Paediatric Investigation Plan submitted to EMA 2 pages 116.9KB
Regulatory Filings
2021-02-24 English
Half Yearly Report and Half Year Accounts 26 pages 1.1MB
Interim / Quarterly Report
2021-02-23 English
Company Secretary Appointment 1 page 129.6KB
Board/Management Information
2021-02-23 English
ANP meeting with US FDA granted for ATL1102 in DMD 2 pages 103.9KB
Regulatory Filings
2021-02-14 English
Quarterly Update and Appendix 4C 8 pages 413.2KB
Interim / Quarterly Report
2021-01-27 English
Proposed issue of Securities - ANP 5 pages 27.3KB
Capital/Financing Update
2021-01-14 English
Appendix 2A 14 pages 299.5KB
Share Issue/Capital Change
2021-01-14 English
Change of Registered Office and Principal Place of Business 1
Regulatory Filings
2021-01-13 English
Ceasing to be a substantial holder 3 pages 126.1KB
Director's Dealing
2021-01-10 English